Wick Capital Partners LLC Acquires New Holdings in Viking Therapeutics, Inc. $VKTX

Wick Capital Partners LLC bought a new stake in Viking Therapeutics, Inc. (NASDAQ:VKTX) in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 85,701 shares of the biotechnology company’s stock, valued at approximately $3,015,000. Wick Capital Partners LLC owned about 0.07% of Viking Therapeutics as of its most recent SEC filing.

Several other large investors also recently added to or reduced their stakes in VKTX. Raleigh Capital Management Inc. raised its holdings in shares of Viking Therapeutics by 58.0% during the 4th quarter. Raleigh Capital Management Inc. now owns 945 shares of the biotechnology company’s stock valued at $33,000 after purchasing an additional 347 shares in the last quarter. Montag A & Associates Inc. boosted its holdings in Viking Therapeutics by 6.4% in the third quarter. Montag A & Associates Inc. now owns 6,620 shares of the biotechnology company’s stock worth $174,000 after purchasing an additional 400 shares in the last quarter. E Fund Management Co. Ltd. boosted its holdings in Viking Therapeutics by 2.4% in the second quarter. E Fund Management Co. Ltd. now owns 17,580 shares of the biotechnology company’s stock worth $466,000 after purchasing an additional 406 shares in the last quarter. Prospera Financial Services Inc increased its position in Viking Therapeutics by 5.1% during the fourth quarter. Prospera Financial Services Inc now owns 9,365 shares of the biotechnology company’s stock worth $329,000 after buying an additional 455 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. increased its position in Viking Therapeutics by 29.5% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 2,109 shares of the biotechnology company’s stock worth $56,000 after buying an additional 481 shares during the last quarter. 76.03% of the stock is owned by institutional investors.

Viking Therapeutics Price Performance

Shares of VKTX opened at $30.38 on Friday. The company has a market capitalization of $3.53 billion, a PE ratio of -7.34 and a beta of 0.69. Viking Therapeutics, Inc. has a one year low of $22.96 and a one year high of $43.15. The company’s fifty day moving average price is $31.56 and its 200 day moving average price is $32.68.

Viking Therapeutics (NASDAQ:VKTX) last released its earnings results on Thursday, April 30th. The biotechnology company reported ($1.37) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.01) by ($0.36). During the same period in the previous year, the business earned ($0.41) EPS. Analysts anticipate that Viking Therapeutics, Inc. will post -4.7 earnings per share for the current year.

Analyst Upgrades and Downgrades

VKTX has been the subject of a number of analyst reports. BTIG Research reaffirmed a “buy” rating and issued a $125.00 price target on shares of Viking Therapeutics in a research report on Friday, May 1st. Wolfe Research assumed coverage on Viking Therapeutics in a report on Thursday, March 26th. They set a “peer perform” rating on the stock. Truist Financial began coverage on Viking Therapeutics in a research note on Wednesday, May 27th. They issued a “buy” rating and a $83.00 price objective on the stock. Morgan Stanley set a $95.00 target price on Viking Therapeutics in a report on Thursday, April 30th. Finally, Cantor Fitzgerald decreased their target price on Viking Therapeutics from $105.00 to $100.00 and set an “overweight” rating for the company in a research report on Thursday, April 30th. Two analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $93.60.

Viking Therapeutics Profile

Viking Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders. Headquartered in San Diego, California, the company’s pipeline leverages small-molecule approaches to target hormone signaling pathways implicated in conditions such as non‐alcoholic steatohepatitis (NASH), dyslipidemia, type 2 diabetes and muscle wasting disorders.

The company’s lead programs include VK2809, a thyroid hormone receptor‐beta agonist designed to reduce liver fat and improve lipid profiles in patients with NASH and dyslipidemia, and VK5211, a selective androgen receptor modulator (SARM) aimed at enhancing muscle mass and function in individuals with muscle wasting conditions.